The Silent Condition:
Managing Long-Term Complications in Hypoparathyroidism

by Dr Afroze Abbas
Consultant Endocrinologist at Leeds Teaching Hospitals NHS Trust

The field of endocrinology is advancing at pace, with many practice-changing innovations emerging.[1] However, hypoparathyroidism (hypopara) is an area of endocrinology where treatment innovation has fallen behind. Unlike with many other endocrine conditions, those treating this rare condition, where insufficient parathyroid hormone (PTH) leads to daily burdensome symptoms, routine access to replacement hormone therapy is not yet available in the United Kingdom.[2] As a result, management often relies on conventional therapies, most commonly calcium and active vitamin D.[2] With these treatments, continuous monitoring and a collaborative approach with the patient, is needed to manage short-term symptom control and long-term health. As a Consultant Endocrinologist for 15 years, I have witnessed first-hand how this can create challenges for both clinicians and people living with hypopara as they navigate the condition.

Navigating the Tightrope: Balancing Symptoms vs Long-Term Risk

Calcium and active vitamin D treatment requires careful balance. If you prescribe too little, the risk of symptoms such as muscle cramps, brain fog, and in some cases seizures, are elevated.[3] Yet, overtreatment can be just as dangerous with serious complications like renal calcifications and soft tissue deposition appearing later down the line.[4]

A key challenge lies in the fact that many people living with hypopara feel subjectively better when their serum calcium levels are above the recommended range, while clinical target recommendations typically lie in the lower range, between 2.1 and 2.3 mmol/L.[5,6]

This creates tension between the short-term symptom relief and long-term risk. Working with patients to understand and accept this balance is a crucial aspect of clinical care, yet adherence and understanding vary significantly.

In my clinical practice, I often see two groups of people living with hypopara who present management challenges. The first are those who are struggling to keep up with treatment who often feel unwell due to suboptimal symptom control. The second group comprise people who are exceeding the recommended calcium and activated vitamin D dosage in an effort to feel better. While this may offer short-term relief, it significantly increases their risk of long-term complications.

For the purposes of this piece, I will focus on the latter group – people living with hypopara who, in seeking to avoid immediate symptoms, may be inadvertently placed at risk of silent but progressive long-term complications.

Addressing the Main Long-Term Complications Associated with Hypopara

Despite being less immediately visible than acute symptoms, long-term complications can significantly impact patient outcomes. Monitoring for and managing these risks requires a proactive and multidisciplinary approach.

Renal complications

Renal complications are among the most recognised long-term risks in chronic hypoparathyroidism.[2] The use of high-dose calcium and activated vitamin D to alleviate hypocalcaemic symptoms can contribute to nephrolithiasis, nephrocalcinosis and chronic kidney disease.[2] Therefore, more frequent monitoring in times of dose change are necessary, on top of routine renal surveillance and imaging that is required for all patients.[5]

Cardiovascular risk
Though less frequently highlighted in clinical discussions, the cardiovascular burden in hypopara is becoming increasingly recognised through emerging evidence – and more research on this is needed. Vascular calcifications, arrhythmias and hypertension present potentially serious long-term risks.[7] Considering cardiovascular assessments, such as blood pressure monitoring, ECGs and imaging into routine care may be an important step towards more comprehensive risk management.

Bone health
People living with hypopara often exhibit elevated bone mineral density (BMD), which has historically led to the assumption of reduced fracture risk. However, despite higher bone density, some studies suggest increased vertebral facture risk, highlighting that bone quality rather than density alone is important. Therefore, vertebral imaging should be considered for patients with chronic hypopara and integrated into long-term monitoring strategies especially for at-risk patients.[8]

Cognitive effects
Neurological and cognitive effects, though frequently reported by people living with hypopara, remain poorly quantified in large studies, highlighting an important gap in research. Patients have reported cognitive dysfunction, fatigue, memory loss and mood changes.[9] Therefore, a more collaborative approach is needed to support people living with hypopara who are experiencing cognitive burden, which can be one of the most debilitating aspects of their condition, given its potential impact on employment, relationships and other aspects of daily life.[9] This should include access to coordinated, end-to-end care involving both neurological and psychological support.

Achieving Better Long-Term Outcomes

In today's hypopara treatment landscape, the current focus on short-term serum calcium correction is not going far enough. Effective management demands a broader and more comprehensive approach that recognises the sometimes silent, but often very debilitating, cumulative burden of long-term complications.

Looking ahead, we must reframe the way we think about hypopara. This includes investment in and implementing more regular and proactive surveillance of long-term complications as listed above, and, wherever possible, expanding access to dedicated clinics and specialist services like the one here in Leeds.

At the same time however, we must continue focusing on patient education and empowerment, to help individuals living with hypopara and their families to better understand their condition and manage symptoms through a collaborative approach with their healthcare professional. Until advancements that reduce the impact of long-term complications become more readily available, we must prioritise actively listening to patients and carefully monitoring them both in the short and long-term term to close the gap between symptom control and long-term outcomes.

ascendis pharma

Seeds of Change is a disease awareness initiative developed and funded by Ascendis Pharma UK Limited and supported by Parathyroid UK and Society for Endocrinology.

[1] Monostra M et al. The changing landscape of endocrinology: GLP-1s, new diabetes technology and more. Healio. Available at https://www.healio.com/news/endocrinology/20250115/the-changing-landscape-of-endocrinology-glp1s-new-diabetes-technology-and-more. Accessed August 2025.

[2] Mitchell DM et al. Long-Term Follow-Up of Patients with Hypoparathyroidism. Journal of Clinical Endocrinology & Metabolism. 2013 Dec; 97(12): 4507-14.

[3] Silva BC. Skeletal and nonskeletal consequences of hypoparathyroidism. Archives of Endocrinology and Metabolism. 2022;66(5):642-50.

[4] Bilezikian JP et al. Management of Hypoparathyroidism: Present and Future. Journal of Clinical Endocrinology & Metabolism. 2016 Jun; 101(6): 2313-2324.

[5] Bollerslev et al. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015 Aug;173(2):G1-20.

[6] Husebye ES et al. Endorcine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022 Oct; 187(6): G1-G21.

[7] Mannstadt et al. The Journal of Clinical Endocrinology and Metabolism: Increased risk of Cardiovascular Diseases in Patients with Chronic Hypoparathyroidism in Sweden. 2025 Apr. 10.1210/clinem/dgaf257.

[8] Björnsdottir S et al. Increased risk of vertebral fractures and reduced risk of femur fractures in patients with chronic hypoparathyroidism: a nationwide cohort study in Sweden. J Bone Miner Res. 2025;40(7):860-7.

[9] Brod M et al. Living with hypoparathyroidism: development of the Hypoparathyroidism Patient Experience Scale-Impact (HPESImpact). Qual Life Res. 2021. Jan;30(1):277-291, doi: 10.1007/s11136-020-02607. Epub 2020 Aug 24. PMID: 32833143; PMCID: PMC7847873.

UK-COMM-2500008 | September 2025